Patients with severe emphysema treated with endobronchial valves (EBV) have been shown to have improved lung function, exercise tolerance and quality of life one year following their procedure. However it comes with a pneumothorax rate of 26.6%. The LIBERATE trial, the largest and longest study of the procedure, was presented at the ATS 2018 and ...
Already a member?
Enter your email to keep reading.